切除不能進行膵癌に対するゲムシタビン・温熱異時併用療法の有効性についての検討

DOI Web Site 被引用文献3件 参考文献24件

書誌事項

タイトル別名
  • Effects of a Sequential Combination of Hyperthermia and Gemcitabine in the Treatment of Advanced Unresectable Pancreatic Cancer: A Retrospective Study

この論文をさがす

説明

Gemcitabine (GEM) has improved both overall survival and tumor-related symptoms in patients with advanced pancreatic cancer when compared to 5-FU, and is a widely accepted treatment for such patients. However, pancreatic cancers remain extremely resistant to chemotherapy. Empiric chemotherapy based on GEM has had no major successes in treating patients with advanced disease. The objective of this study was to evaluate the response rate, survival, and toxicity of the sequential combination of GEM and hyperthermia. Between November 2005 and November 2007, 7 patients with unresectable pancreatic cancer received sequential combination therapy with GEM and hyperthermia at the Matsushita Memorial Hospital. Data were then compared with 7 historical controls treated with GEM alone at the same institution. There were no significant differences in age, performance status or UICC stage between the GEM plus hyperthermia and GEM monotherapy groups. The disease control rate (CR+PR+SD) was 14.3% for patients treated GEM alone and 57.1% for patients treated with GEM plus hyperthermia. The median survival time was 198 days for patients treated with GEM alone, and 327 days for patients treated with GEM plus hyperthermia. Combination therapy with GEM and hyperthermia thus improves overall survival when compared with GEM monotherapy (p=0.0275). The sequential combination of GEM plus hyperthermia showed a potential therapeutic effect, and was at least as effective as GEM monotherapy. To clarify the effects of this combination therapy, a larger prospective clinical trial is required.

収録刊行物

  • Thermal Medicine

    Thermal Medicine 24 (4), 131-139, 2008

    日本ハイパーサーミア学会

被引用文献 (3)*注記

もっと見る

参考文献 (24)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ